Cancer Trials That Help Patients Most Are About to Lose Funding — Here's Why

A proposed rule change threatens the cancer trials that actually help patients. Here's what to do. #CancerResearch #ClinicalTrials #ElevatingCancerTreatment

👉 Get your free guide, '10 Things to Elevate Your Chemo Journey'

👉 Want personalized attention to help you along your individual cancer journey? Explore 1:1 sessions with Dr. Chaplin

👉 Want to find out more about Dr. Chaplin's journey of bringing a cancer drug to market? Explore his innovations

--------------------------------------------
Episode Description:

There's several categories of cancer research that pharma companies will never pay for.

Small trials. Drug comparisons. Repurposed generics. The kind of data we cover here.

That research runs on grants. And those grants are about to become a lot less secure.

In this blog/video, Dr. Chaplin explains what's happening — and why it matters to you as a cancer patient:

• Why pharmaceutical companies will never fund certain types of clinical trials
• What the proposed OMB rules change actually does to long-term research funding
• How a five-year trial disappears when the money stops halfway through
• What happens to cancer treatment options if this goes through
• What you can do about it before July 13th, 2026

--------------------------------------------

Inquiries: 

info@elevatingcancertreatment.com

https://elevatingcancertreatment.com

--------------------------------------------

Disclaimer:
The information provided in this podcast is for educational and informational purposes only, and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard or read in this podcast or on this channel.
Reliance on any information provided by Dr. Jay Chaplin or Elevating Cancer Treatment is solely at your own risk. Dr. Jay Chaplin is a scientist and drug developer, not a medical doctor providing patient care. The content presented here reflects general scientific understanding and research, and may not be applicable to your individual health circumstances. Individual medical conditions and treatments vary, and no two situations are exactly alike.
Always consult with your personal healthcare provider before making any decisions about your health or treatment plan.

Transcript

SPEAKER_00 0:00

So many of you come to this channel because we don't just talk about large trials and big drugs. We also talk about small clinical trials from tiny university departments or independent hospitals. We talk about trials that compare drugs against each other, which pharma companies rarely do. We talk about trials that combine drugs or generic drugs or look at repurposing drugs. And I want to tell you today that the ability to do that, the ability to even generate that data in the first place, is in danger. It's in danger right now, and there's something you can do about it. I am personally asking you a favor. My name is Jay Chaplin, as you know. I am a PhD, not an MD. I am a medical researcher, not a classical doctor. I design drugs and I look at clinical trial data to see what works and what doesn't, and to try and figure out better ways to impact cancer. And that's what we try and share here. Now, right now, for the next month, there is a very dangerous time and an unprecedented opportunity for you to have an impact on cancer research and indeed scientific research in general within the United States. The Office of Management and Budget is attempting to push through a set of rules changes. And no matter what you think about this current administration and politics and whether research should be done the way that it is, I certainly think it could use a lot of tuning up, what's being proposed is very dangerous and will have a chilling effect on biomedical research and especially cancer research within the United States if it's ratified. I'll talk about what that is, or at least a subset of it. I'll talk about what you can do. I do want to thank our friends at the Your Local Epidemiologist podcast and newsletter for bringing great tools to our attention, including the one we'll be linking down in the description below later. So I'd like you to stop and think about any scenario in which you need to do something, you want to do something, that requires a large amount of money that you don't have. For most of us in the consumer space, and this is not a great metaphor, what we would do is we would go to the bank, we would get a loan, and then we would pay it back over time. So that is an imperfect metaphor, but it's the best one I can come up with for the granting scenario that we're in. Many of these small clinical trials, again, from universities, from individual hospitals, they can cost millions of dollars. Those are done not with funds from the university. The university doesn't have that money. They're not going to fund that. Hospitals don't have that money, they're not going to fund that. Pharmaceutical companies do, but they're only going to fund trials on their drugs, not on comparing their drug to another company's drug, certainly not for another company's drug, certainly not for a generic drug, or for general metabolic research. So if you care about any of those things, this is for you. If you want to do a clinical trial for any of those other scenarios, anything other than getting a new drug out, that requires grant money. Because you need a large chunk of money over a span of time, it's a long span of time. If you're doing a five-year trial, it's probably at least a six-year grant. Because you need to ramp up, you need to run through the whole five years of the trial, and, well, it's actually longer than five years, because if you're going to follow every patient for five years, your first patient doesn't accrue at the beginning. A five-year trial may take you seven to ten years, depending on how fast you can accrue patients. But you follow them all the way through, and then you still have to do the data analysis and publication at the end. That is a long period of time to be paying for a trial. So imagine you're in that situation, you're gonna buy a house, you're gonna buy a car, you go to the bank, you get a loan, you are faithfully paying, you're doing everything that you're supposed to, and all of a sudden the bank decides halfway through, you know, we don't like this arrangement, we're pulling all of our money back. If you don't want your house foreclosed on, you've got to come up with the rest of the money yourself. Again, not a great metaphor, but the best one that I've got. That is essentially one of the options that's being pushed through with this new rules change for the OMB. That a grant, that let's say it's a five-year grant, a grant that is awarded as a five-year grant can be stopped, completely, disappear at any time and for any reason. There is no guarantee. Think about that. What kind of impact will that have on biomedical research and clinical trials if money that you are counting on for the next five years to pay salaries and to follow patients and to finish a clinical trial or finish a set of lab experiments can disappear at any moment with no warning? That's what we're headed toward. We can argue about the politics of all of the other pieces, but this one in particular is very easy to understand. Commitments no longer mean anything. Long-term financial commitments are revocable instantly. That's the world that we're heading for. So what can you do? It's as simple as writing a letter. Again, there is a lovely resource brought to our attention. There's a link down below in the description as usual. If you follow that, scroll toward the bottom. There is a template for how to write a letter objecting to this new rules change, where to send it and by when? Middle of July. You have one month. You have one month. Send the letter. If enough letters come through, they have to be dealt with. The rules have to be amended in order to deal with those concerns. This is why we're not asking you to sign a form letter that we're attaching. A form letter, all of them will be counted as one response. If you follow the template and personalize it and make it yours, talk about the impact to you, to your family, to your friends for having cancer research dry up and having only large pharmaceutical companies be able to do clinical trials. Think about that world. Think about the impact that that world would have on you and your life. Use that to write your letter. In that way, every letter will be individual and every letter will be counted independently. That's the way to have your letter count. That's the way to have your vote in this circumstance count. Please, please do write that letter. Please send it before July 13th. It does have to be postmarked. Follow the template down below, and please help me save the U.S. biomedical research ecosystem. If you care about good research options and good treatment options, this is something we can do together to have an impact and preserve that for future generations. Even your own. This is something that will play out over the next five to ten years. Even if it's reversed, it will have a chilling effect on research for at least five to ten years. This is your chance to have an impact. Beyond these videos, if you need more personalized guidance or a deeper dive into specific treatments to have your treatment be as effective as possible, I offer one-on-one sessions and medical advocacy. You can find information on our website, which is linked down below. Again, if you found this video informative, please give it a thumbs up, click the notification bell, and subscribe to our channel for more science based cancer insights.